

Cardiovascular and metabolic side effects in patients using anti-depressants or antipsychotic medications. A mixed method systematic review

Jalal, Zahraa; Paudyal, Vibhu; Azfr Ali, Ruba

Citation for published version (Harvard):

Jalal, Z, Paudyal, V & Azfr Ali, R 2018, *Cardiovascular and metabolic side effects in patients using anti-depressants or antipsychotic medications. A mixed method systematic review..*

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Title: Cardiovascular and metabolic Side Effects in Patients Using Anti-depressants or Antipsychotic Medications: A Systematic Review Protocol.

TABLE OF CONTENTS

1	Background:	4
1.1	Mortality burden and physical comorbidities among people with mental health conditions: 4	
1.2	Antipsychotic and antidepressants as independent risk factors for cardiovascular and metabolic comorbidities in people with mental health conditions:	4
1.2.1	Antipsychotic medications:	5
1.2.2	Antidepressants medications:	6
1.2.3	Clinical implications:	8
1.3	Current practices in managing cardiovascular co-morbidities associated with antipsychotics and antidepressant drugs:	9
1.4	Why it is importance to conduct this review?	10
1.4.1	Rational of the review: (purpose statement).....	10
1.4.2	Objectives of the study:	11
1.4.3	Review questions:	11
2	METHODS:.....	11
2.1	Reporting guidelines:	11
2.1.1	P: Populations	11
2.1.2	I1: Interventions.....	12
2.1.3	I2: Phenomena of Interest	12
2.1.4	O: Outcomes measures.....	12
2.1.5	C1: Context.....	12
2.1.6	C2: Condition.....	13
2.1.7	S: Study design:	13
	Search limitations:	13
2.2	Search strategy	13
2.2.1	Information sources:	13
2.2.2	<i>Electronic sources:</i>	13
2.2.3	<i>Searching additional sources to locate relevant literature:</i>	13
2.2.4	List of Search terms:.....	13
2.3	Study selection process:.....	14
2.4	Assessment of methodological quality:	14
2.5	data extraction:.....	14
2.6	Synthesis of the results:	15
2.6.1	Quantitative data:	15
2.6.2	Qualitative data: Practitioners and patients prospective	15

3	References	16
---	------------------	----

1 BACKGROUND:

1.1 MORTALITY BURDEN AND PHYSICAL COMORBIDITIES AMONG PEOPLE WITH MENTAL HEALTH CONDITIONS:

According to the world health organization (WHO), mental health conditions are defined as set of diseases that are mainly characterized by abnormalities in thought, behaviour and emotion in a way that may hinder their effective interaction with other people (1). Furthermore, mental health conditions are clinically diagnosable disorders that may sustain for long period or demonstrate recurrent pattern during the life. Mental health conditions are considered universal disorders that affect people at wide range regardless their age and geographical location (2,3). Around of 50% mental health condition including schizophrenia are most likely diagnosable by the age of 14 and years old age. People with major mental health conditions such as schizophrenia and depression experience around 40 to 60 % higher chances of premature death compared to the general population(1).

Cardiovascular diseases have been reported to be a major cause of death in patients with mental health conditions (4,5). Patients with schizophrenia show an increased rate of mortality due to cardiovascular diseases (13). The aetiology of cardiovascular complications in people with mental health conditions is multidimensional in nature, which includes several aspects such as life style factors, genetic factors and cardiovascular related diseases. The high mortality that are observed in this population was suspected to be linked to the increased rate modifiable cardiovascular risk factors (5). Prevalence studies indicate that modifiable cardiovascular risk factors such as diabetes, abnormal lipid profile, glycemic abnormalities, weight gain, serious alterations in the cardiac-conductivity (6), hypertension and insulin resistance , are highly prevalent in patients with psychotic illness such as schizophrenia and depression (5,7). Although, the exact underlining cause of cardiovascular complications in patients with mental conditions is not well defined (5), there is a growing body of evidence which have addressed the possible association between the use of antipsychotics, antidepressants and the increased incidence of cardiovascular disease (CVD) in people using these medications. However, the majority of previous work addressed several confounding factors other than the effect of the targeted psychotropic drugs for example life style and genetic factors. This makes difficult to build a conclusive estimation of the actual impact of antipsychotics and antidepressants on the prevalence of CVDs.

1.2 ANTIPSYCHOTIC AND ANTIDEPRESSANTS AS INDEPENDENT RISK FACTORS FOR CARDIOVASCULAR AND METABOLIC COMORBIDITIES IN PEOPLE WITH MENTAL HEALTH CONDITIONS:

One particular interest to researchers and clinicians is the increased risk of cardiovascular complications (CVCs) and their associated risk factors with the use of psychotropic medications. Evidence provided by Wu CS et al (6) and others (7) through the results of the review that was done to evaluate the cardiometabolic characteristics for individual psychotropic classes, which revealed that antipsychotic drugs and other psychotropic agents such as antidepressants have the potential to causes cardiovascular risk factors or accelerate pre-existing ones. The adverse effects on the cardiovascular system can be caused by different mechanisms which are beyond the focus of this section, however, this effect can be caused either by direct action on the heart or through indirect cascade of metabolic dysregulations which can finally lead to adverse cardiac events (8).

Antipsychotic medications are widely used in the management of schizophrenia and other mental health conditions. Antipsychotic drugs are classified into two major classes. The first class is known as typical antipsychotics or first generation antipsychotic drugs (FGAs). This group is characterized by their effectiveness in relieving positive psychotic symptoms of schizophrenia such as hallucinations. However, they have been proved to be less effective against negative symptoms, which lead to the development of the new generation of antipsychotic drugs which are known as second generation antipsychotic or atypical antipsychotic drugs (9). Second generation antipsychotic drugs are more effective than typical antipsychotic drugs in relieving negative symptoms, so the compliance to therapy would increase hence decrease frequency of relapse (10)

Antidepressants on the other hand, are considered a typical intervention to manage people who suffer from depressive mood disorders and other psychotic disorders such as depressive schizophrenia. In the future, it is estimated that mortality due to cardiovascular diseases along with depressive diseases will be escalated globally (11,12). Moreover, some studies revealed that depressive disorders tend to be associated with more prevalence of cardiovascular risks (13).

1.2.1 Antipsychotic medications:

At normal therapeutic dose first generation antipsychotic drugs (FGAs) have been known to cause motor abnormalities mainly extrapyramidal symptoms (EPS) (9,10). Second generation antipsychotic drugs, on the other hand, have less motor side effects compared to the previous generation. Moreover, the extrapyramidal symptoms (EPS) caused by second generation antipsychotic drugs (SGAs) tend to be dose dependent with achievable therapeutic effect that is free of extrapyramidal symptoms (EPS), which makes second generation antipsychotic drugs (SGAs) more preferable over the first generation antipsychotic drugs (FGAs) (10). However, second generation antipsychotic drugs have similar cardiovascular risks that represented in their negative effects on the cardiac conductivity, vascular changes and metabolic homeostasis.

1.2.1.1 Cardiovascular side effects of antipsychotic drugs:

Antipsychotic drugs are known to cause cardiac arrhythmia as well as orthostatic hypotension (18). In healthy population, the QTc interval ranges from 380 to 450 milliseconds (ms) and this can vary according to patients' age and gender. QT prolongation can be defined as > 450 to 460 ms increase above the normal physiologic range (14). Both generations of antipsychotics have the capability to cause electrocardiogram (ECG) changes (14). Epidemiologic studies (6,15) correlate this lengthen in QTc interval with the increased risks of sudden death that have been reported among patients using antipsychotic drugs. Antipsychotic drugs associated with this risk include but are not limited to haloperidol, olanzapine, quetiapine, risperidone and sulpiride (6). The arrhythmogenic effect caused by antipsychotic was reported with high doses of antipsychotic drugs, however, this effect can occur at normal therapeutic doses. Therefore, determining the need for regular ECG monitoring can be challenging. Furthermore, antipsychotic drugs have been reported to cause changes in blood pressure. Orthostatic hypotension is the most frequent vascular effect of antipsychotic drugs. Up to 40% of patients treated with antipsychotic reported to suffer from sudden drop of blood pressure at standing. Orthostatic hypotension can be defined either as ≥ 20 mmHg reduction in systolic blood pressure (SPB) or ≥ 10 mm Hg decrease in diastolic blood pressure (DBP) after standing for 3 minutes (16). Notably, the hypotensive effect tend to occur at the early phase of psychotic treatment (16), however, it is not clear whether this effect is dose dependent knowing that loading dose regimen is commonly utilised at the early stages of psychotic treatment. Besides, the orthostatic hypotensive effect have been proved to be common among elderly patients treated with antipsychotic therapy and orthostatic hypotension is general concern in old patients treated with antipsychotic drugs as risks of falls would be magnified.

1.2.1.2 *Metabolic side effects of antipsychotic drugs:*

Weight gain is a major components of the metabolic dysregulations that caused by antipsychotic drugs (7,9) and its considered a major risk factor for cardiovascular diseases (CVDs). The effect of weight gain can vary among different antipsychotic classes (7,9), since it was more frequent with SGAs. Moreover, there is a hierarchical effect on the risks of weight gain among antipsychotics drugs, that has been confirmed by different studies (7,9,17). Several clinical studies () showed that second generation antipsychotic drugs (SGAs) primarily clozapine and olanzapine demonstrate greater weight inducing effects compared to other antipsychotic drugs (15), in addition to other lipid associated risk factors such as dyslipidemias and insulin resistance. Some studies highlighted that specific patients characteristics such as age and degree of exposure to antipsychotic drugs may increase risks of weight gain (9). Young patients have been reported to be the most susceptible to metabolic dysregulations including weight gain. This is highly important when considering the fact that some mental health conditions such as schizophrenia and depression tend to develop at young age and may continue to progress in later life (18), and the antipsychotic induced weight effect have been suggested to be persistence and even be cumulative(19). This may indicate warning signs of increased risks of cardiovascular disorders due to obesity at early stages of life.

Other metabolic dysregulations have been associated with the use of antipsychotic drugs such as dyslipidemias, which apparently associates with the body weight. Second generation antipsychotics mostly clozapine and olanzapine have been associated with the higher tendency to cause dyslipidemias mainly hyperlipidemia and hypertriglyceridemia (7).Hypertriglyceridemia induced by antipsychotics can be developed rapidly as the level of triglyceride (TG) can be doubled within two weeks after initiating the treatment with antipsychotics (7). Consequently, antipsychotic drugs have been reported to cause metabolic syndrome (MS). A cluster of abnormalities that associate with metabolic disturbances including central obesity, dyslipidemias, plasma glucose abnormalities, and hypertension (20). Results from a prevalence study (21), reported a considerable increase in rate of metabolic syndrome among patients treated with antipsychotic drugs, as 40.2% of the participants were diagnosed to have metabolic syndrome. Some metabolic criteria that identify patients with metabolic syndrome (MS) have been previously addressed to be associated with the use of antipsychotic drugs and hence the increased risk for cardiovascular diseases and other metabolic conditions such as diabetes mullets (DM). Moreover, patients with metabolic syndrome (MS) have been reported to have high risks of developing cardiovascular and metabolic diseases such as coronary heart diseases and diabetes.

1.2.2 Antidepressants medications:

The exact pathophysiology between the cardiovascular events and depression still not well established. Amongst the suggested explanations is the potential role cardiovascular side effects of antidepressants that may adversely affect the outcomes of people suffering from cardiovascular disease (22). Several studies showed an accelerated rate of cardiac mortality among antidepressants users.

1.2.2.1 *Cardiovascular side effects of antidepressants*

With regard to the safety of antidepressants drugs, previous work that addressed the safety of antidepressants in people with cardiac diseases, highlighted the indirect role of antidepressants on reducing the cardiovascular risks by improving the depressive symptoms. For example, (28), selective serotonin reuptake inhibitors (SSRIs) class were mainly investigated according to their effectiveness in improving the cognitive symptoms in patients with depression and hence the general outcome on their health would improve accordingly. Certain classes of antidepressants primarily tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have been well

established for their tendency to negatively affect the cardiac conductivity which can lead to fatal arrhythmias (11,23). Additionally, the arrhythmogenic side effect of antidepressant drugs revealed to be dose dependent (24) who reviewed the causes of cardiovascular incidents from that can result from non-cardiac drugs. Hypertension was also reported with antidepressant drugs (7). In meta-analysis study of the cardiovascular adverse effects of psychotropic drugs, antidepressants such as venlafaxine and imipramine significantly increased the diastolic blood pressure (DBP) by 1.2mmHg and 1mmHg respectively (25).

1.2.2.2 Metabolic side effects of antidepressants:

Notably, the majority of the available data regarding the metabolic effects of antidepressants focus on their effects on the weight, however controversy exist regarding the effects of antidepressants on weight gain. Some authors suggest that the increase in weight might result from the improvement of depression symptoms as a result of the improved appetite of the patient. However, others argued this view by claiming that weight gain can be a cumulative effect of antidepressant treatment since it tends to be common during the acute phase of treatment and may continue after treatment cessation (7). With respect to antidepressant drug classes, older classes such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MOAIs) have been reported to have cause weight gain more than other antidepressants classes (26). Results from meta-analysis to investigate the risks of weight gain associated with different antidepressant drugs, showed significant increase in weight from the baseline that range from 1.5kg, 1.7kg and 2kg caused by amitriptyline, mirtazapine and nortriptyline respectively over a 4–12-week period(27).

Newer antidepressant classes were also associated with substantial effect on weight. Recent review that highlights the rate of significant weight gain and factors associated with weight gain among antidepressants treated patients, pointed out that mainly paroxetine and citalopram were associated with significant weight gain, while other newer antidepressants classes may be considered to have neutral effect (28). Notably, the weight gain induced by antidepressant drugs has been reported to be associated with the duration of treatment, since this effect tends to be heightened with the increase duration of treatment. Long phase trials (16–46 weeks)(29) that compared the weight changes among patients treated with nefazodone (n=523) and selective serotonin reuptake inhibitors (SSRIs) (fluoxetine, paroxetine, and sertraline; N = 513), demonstrate that around 8.3% of patients treated with nefazodone and 17% of patients treated with selective serotonin reuptake inhibitors (SSRIs) experienced more than 7kg increased in weight. This may indicate that the weight inducing effect of antidepressants can be cumulative. However, it is not clear whether the weight inducing effects of antidepressant drugs can be reversed after ceasing the antidepressant treatment.

In addition, antidepressants have been reported to cause glucose dysregulations, major components of metabolic syndrome. In general, tricyclic antidepressants (TCAs) are the main class that reported to be associated with hyperglycaemic activities (7). Limited data are available regarding the effect of antidepressant drug on other metabolic abnormalities such as dyslipidaemias (7) and insulin sensitivity, regardless the strong evidence that was provided by the study that investigated the predictors for development of metabolic syndrome among depressive patients, which shows significant association between the use of antidepressants mainly tricyclic antidepressants (TCAs) and the risks for development of certain components of metabolic syndrome (MS) particularly dyslipidemia and hypertension (95% CI, OR; 1.8 to 2.57), consequently increased risks of metabolic syndrome (MS)(30).

1.2.3 Clinical implications:

Recent review of the cardio metabolic side effects of psychotropic drugs showed a considerable variation in the metabolic effects among the different psychotropic drug classes. Currently, a head to head comparison between cardiovascular and metabolic side effects caused by different psychotropic medications (i.e. both antipsychotics and antidepressants in this context) is lacking. According to the review, the weight inducing effects that caused by antidepressants is considered lower than the effect induced by antipsychotics. For example, antidepressants tend to cause a relatively low increase in body weight, around 1.5-2 kg over 4 to 12 weeks period. In the contrary, the weight inducing effect of antipsychotic drugs was higher than the effect produced by antidepressants as they were reported to cause more than 7 kg raise in weight from the baseline after only 4 weeks treatment period (31). Regarding this difference it is essential to appreciate that the utilisation of co-treatment regimen with antipsychotic and antidepressants is a common practice in mental health (32), which can result in substantial underestimation of the synergism effect that can result from this combination.

In practice, when considering treatment with antipsychotic drugs, the use of single agent antipsychotic is more preferred over the use of combined antipsychotic therapy (33). However, resistance to antipsychotic treatment is a common problem among patients treated with antipsychotics. According to the National Institute of Health and Care Excellency (NICE) (34), atypical antipsychotic drugs mainly clozapine is preferred when response to first line antipsychotic therapy is lacking. By outweighing the risks of using drug with significant cardiovascular effects against the benefits of having better symptoms control, measures to reduce the adverse effects of the drug can be applied. As previously mentioned, combination therapy with antipsychotic drugs is not preferable, however, large proportion of patients with mental health conditions are treated with more than one antipsychotic drugs (15) Antipsychotic can be used in combinations with other psychotropic drugs for example antidepressants. Since psychotic symptoms can be manifested as depression, antidepressants can be considered to alleviate the depressive symptoms and improve the overall clinical outcome. Paradoxically, most preclinical and clinical trials on cardiovascular side effects of antipsychotic drugs and their associated risk factors focus on the effects of exposure to a single psychotropic agent.

Antidepressant drugs on the other hand, are considered mainly in patients experiencing moderate to severe depressive symptoms (26). Furthermore, tricyclic antidepressants (TCAs) are not considered a first line option in the treatment of depression (35) since the introduction of the newer antidepressant classes such as selective serotonin re-uptake inhibitors (SSRIs). Owing to their effectiveness in improving depressive symptoms along with their relatively safe cardiac profile. This was supported by the results of a meta-analysis that shown that selective serotonin reuptake inhibitors (SSRIs) have significantly lowered the level of depressive symptoms compared to the placebo. Similar results were found by number of trials that studied the efficacy of selective serotonin reuptake inhibitors (SSRIs) on relieving depressive symptoms although significance was a major issue in these studies (36). However, the use of other antidepressant classes for example tricyclic antidepressants (TCAs) remain a considerable option when response to the first line class (SSRIs) is lacking. Recent advances in management of depression (32), support the use of augmented therapy with antipsychotic drugs in the management of refractory depressive episodes. As shown by the results of the meta-analysis that investigated the effectiveness of combined therapy of

antidepressants and antipsychotic in treating patients with depression, augmented therapy with antipsychotic was superior to treatment with conventional antidepressants mono-therapy (32).

1.3 CURRENT PRACTICES IN MANAGING CARDIOVASCULAR CO-MORBIDITIES ASSOCIATED WITH ANTIPSYCHOTICS AND ANTIDEPRESSANT DRUGS:

As suggested by many studies(37,38) early intervention is crucial to compensate cardiovascular complications that can be induced by antipsychotic drugs. Previously, there was no clinical guidance for health care providers that assist clinical monitoring of cardiovascular or metabolic side effects of psychotropic drugs. Consequently, prescribers relied mainly on their knowledge along with their professional experience. Based on the results from The Clinical Antipsychotic Trials of Intervention Effectiveness CATIE (21), the European Psychiatric Association (EPA)(5) in collaboration with the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) have published a statement which aims to improve physical health care for mentally ill people. The intention was to support the need for regular monitoring and screening of cardiovascular diseases and their risk factors among people taking antipsychotics and antidepressants (5).

In order to maximise screening and monitoring among patients treated with psychotropic drugs, several strategies have been introduced in practice aiming to minimize cardiovascular and metabolic side effects that can be caused by psychotropic medications. These strategies range from simple act such as adding drugs that can reverse or attenuate the adverse metabolic effects of psychotropic drugs to include more complicated behaviour for example adopting a healthy life style (9,31,39). Generally ,strategies can be divided into: pharmacological and non-pharmacological (40).

In the context of mental health conditions, non-pharmacological interventions focus mainly on behavioural changes, in which affected people adopt certain measures for example life style modifications and educational programs. These interventions have been intended mainly to improve physical health in patients with mental health conditions. However, methodological variabilities such as sample size, duration of interventions and differences in intervention approaches themselves make it difficult to make conclusive estimation of their effectiveness. Pharmacological interventions, on the other hand, are strategies refer to acts that concern the use of medications. It may include proper selection of medication, switching between drugs and the use of adjunctive agent. Other forms of pharmacologic interventions such as screening and monitoring of cardiovascular side effects have been addressed in several trials (41–43).

The selection of medication with preferable safety profile can be applied in patients with increased risks for a particular side effect. It includes the proper selection of drug dose and dosage formulation. Switching to a safer drug can be considered when adverse drug effect is suspected (44) or adjunctive drug can be added to attenuate or reverse the side effect of a concomitant agent. Few studies have considered switching for medication with favourable side effects profile as a major intervention to minimize the cardiovascular side effects of the utilized antidepressant drugs (45). Results of a review that investigated the different interventions to manage weight gain and metabolic disturbance in patients taking antipsychotic drugs (31) suggest that pharmacologic interventions primarily, switching between medications along with choosing the proper drug, are considered the most effective strategies to minimise weight gain. This is particularly useful when early non-pharmacological intervention is inadequately effective. However, even when physical

health issues are developed, evidence indicates that many health care professionals tend to be hesitant to switch to psychotropic with better side effects profile. This indicates an urgent need to identify factors that hinder the application of pharmacological interventions in patients treated with psychotropic drugs.

So far, the majority of the proposed strategies to manage cardiovascular and metabolic side effects of psychotropic drugs focus on utilising non-pharmacological approaches. Such strategies are mainly based on behavioural modifications that encourage subjects to adopt behavioural changes which have positive impact on their life. An example of this, programs that are designed to aid weight management and smoking cessation (46). Furthermore, the majority of the proposed work focus on managing weight gain and physical health of patients treated with antipsychotic agents. Number of trials have focused on pharmacological interventions primarily the ones that lessen or antagonise that weight inducing effect of antipsychotic drugs (anti-obesity agents). Among the most commonly investigated agents are metformin and nevertheless, the safety and the clinical efficacy of some of the proposed anti-obesity drugs have not been established yet. Nevertheless, other forms of pharmacologic interventions such as switching between medications are not extensively investigated in the literature. Therefore, it is difficult to rely on this results if we considered that other potential effective approaches such as adding adjunctive drug and switching to safer drug may not be properly undertaken in real practice.

1.4 WHY IT IS IMPORTANCE TO CONDUCT THIS REVIEW?

There is no clear data from systematic reviews and meta-analysis regarding the prevalence of cardiovascular and metabolic comorbidities and their predisposing factors among patients with mental diseases which are associated with the use antipsychotic and antidepressants drugs. As indicated by several epidemiological studies (45) the prevalence of schizophrenia and depression continues to increase, which indicates a potential rise in the prescribing patterns of psychotropic medications worldwide. Furthermore, despite existing guidelines and recommendations, many antipsychotic and antidepressant drug-treated patients are not adequately assessed for easily measurable metabolic and cardiovascular risk factors, such as dyslipidemias and blood pressure (38). Most evidence points out that metabolic and cardiovascular comorbidities in people using antipsychotic and antidepressant medications are underdiagnosed. For instance, data generated from CATIE trial (41), which aimed to examine a multitude of variables in patients with schizophrenia that increases the incidents of metabolic syndrome (MS), demonstrate a significant variation in the level of management among elements of metabolic syndrome (MS). This included lower rate of screening and treatment of major cardiovascular risk factors such as hypertension and dyslipidemias, however, the study did not highlight any possible reasons for this low rate of treatment among the targeted population. Barriers to effective interventions in practice include resisting behaviour of patients with mental health conditions, time constrain and the availability of the necessary equipment may have possible impact.

1.4.1 Rational of the review: (purpose statement)

As proposed above, in order to alleviate cardiovascular and metabolic complications, which can be caused or aggravated by antipsychotics and antidepressants medications, careful follow-up with routine monitoring of cardiovascular disease and its related risk factors side effects at early stages might facilitate successful management of the complications and hence provide better prognosis. In

order to accomplish that, representative epidemiological data are critical in order to estimate the impact cardiac and metabolic related side effect of, mainly antipsychotics and antidepressants, on public health. Beside it is important to review the nature and effectiveness of interventions aimed to monitor and manage the cardiovascular and metabolic side effects of these medicines.

1.4.2 Objectives of the study:

- ❖ To identify the prevalence and incidence of cardiovascular and metabolic side effects in patients taking antidepressants and antipsychotic medications.
- ❖ To identify the nature of interventions and their effectiveness around assessment, screening, monitoring, management cardiac and metabolic side effects of antipsychotics medications.
- ❖ To identify the extent to which patients taking antidepressants & antipsychotics are assessed, screened, monitored and managed for cardiac and metabolic side effects.
- ❖ To explore the perspectives of health care providers regarding the assessment, screening, monitoring and management of cardiac and metabolic side effects in patients taking antipsychotic or antidepressant medications.
- ❖ To explore patients' perspectives regarding the assessment, screening, monitoring and management of cardiac and metabolic side effects related to the use of antipsychotic and antidepressant medications.

1.4.3 Review questions:

- What are the incidence and prevalence of cardiac and metabolic complications that are correlated to the use of antipsychotic and antidepressant medications?
- What are the different interventions to manage cardiovascular and metabolic side effects of antipsychotic and antidepressant medications that have been proposed in the literature?
- Is there current evidence which support the effectiveness of regular assessment, screening and monitoring of cardiac and metabolic side effects of antipsychotic and antidepressant medications?
- How often patients using antidepressant or antipsychotics are assessed, screened, monitored and for cardiac and metabolic risk?
- What are the possible barriers for assessing, screening and monitoring the targeted side effects in patients using antipsychotics and antidepressants?

2 METHODS:

2.1 REPORTING GUIDELINES:

The review protocol has been drafted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement (47). The review will be conducted as per the Cochrane guideline for systematic reviews (48) and Centre for Review and Dissemination (CRD) (49). Reporting of the review including results of the literature searching, screening, data extraction and the applied inclusion and exclusion criteria will conform to Preferred Reporting Items for Systematic Reviews and Met-Analysis (PRISMA) statement and checklist. This review will be part of a dissertation for a doctoral degree. Eligibility criteria for inclusion:

2.1.1 P: Populations

- **P 1:** Adult patients aged ≥ 18 years old.

- Using one or more antipsychotics drugs or antidepressant therapy or a combination, for mental health conditions.
- **P2:** Health care professionals involved in the care of the patients.
- **P2:** Patients prescribed antipsychotics/antidepressants for mental health conditions

Special inclusion criteria for studies to be selected for the prevalence purpose:

- **P3:** patients of all ages receiving antipsychotics or antidepressants or both.

2.1.2 I1: Interventions

Interventions related to the assessment, screening, monitoring of cardiac and metabolic side effects related to antipsychotic and antidepressants.

2.1.3 I2: Phenomena of Interest

Views, experiences, behaviors of health care professionals and patients regarding the assessment, screening and monitoring of cardiac and metabolic side effects of the antipsychotics and antidepressants.

2.1.4 O: Outcomes measures

2.1.4.1 Primary outcomes:

- Incidence or prevalence of cardiac or metabolic side effects of antipsychotics and antidepressants.
- Nature of interventions that are proposed in the literature for example: pharmacological and non-pharmacological interventions.
- Improvement or worsening of pre-existing cardiac or metabolic condition induced by antipsychotics and antidepressants.
- Experience of patients receiving the interventions, for example: Patients' satisfaction with care provided to manage cardiovascular and metabolic complications of antipsychotics and antidepressants.
- Perspectives of health care providers regarding the delivery of care for example, barriers and facilitators to screening or management of cardiovascular side effects and their associated risk factors in patients using antipsychotics and antidepressants.

2.1.4.2. Secondary outcomes:

- Any other patient-reported outcomes other than symptom improvement for example their quality of life.
- Hospitalisation or re-admission primarily related to cardiac or metabolic complications in patients prescribed antipsychotics and antidepressants.
- Health care professionals and patients' awareness, views and experiences of the cardiovascular and metabolic risks associated with the use of antipsychotics and antidepressants.

2.1.5 C1: Context

- Patients with mental health conditions using antipsychotics or antidepressants as major treatment for the primary condition (depression or psychosis).
- Any clinical settings.

2.1.6 C2: Condition

- Prevalence or incidence of cardiovascular and metabolic side effects and their risk factors in patients diagnosed with mental health conditions using mention the two classes of drugs.

2.1.7 S: Study design:

All designs that reported either incidence, prevalence or interventions to manage cardiovascular side effects of antipsychotics or antidepressants medications will be included for the review, however, studies will be excluded if they meet one of the following exclusion criteria:

- Case reports.
- Literature reviews.
- Discussion and view point studies.
- Grey literature
- Abstract only publications.

SEARCH LIMITATIONS: English language only, full text publications and studies focused on human, date limit Studies from year 2003 (last 15 years) and onward will be searched (2003). This date limit also coincides with the warning statements that issued by the the Food and Drug Administration (FDA) regarding the increased risks of diabetes induced by second generation antipsychotic drugs (50).

2.2 SEARCH STRATEGY

2.2.1 Information sources:

2.2.2 *Electronic sources:*

The following databases will be searched in order to identify for relevant literature including:

- EMBASE
- MEDLINE
- PubMed
- Cochrane Central Register of Controlled Trials
- PsycINFO
- CINAHL

2.2.3 *Searching additional sources to locate relevant literature:*

- Personal contact: researchers will be contacted if necessary to gain information for clarification purposes and access to raw material when needed.
- Cross-referencing of bibliographies: reference list of the identified relevant studies will be scanned including reviews and primary studies.

2.2.4 List of Search terms:

The search strategy combines 4 facets of search terms:

- Antipsychotic and antidepressants medications.
- Cardiovascular and metabolic related side effects.
- Intervention
- Prevalence

A scoping search will be undertaken against each database to inform how the search terms are being translated in each database and hence identify the corresponding text words in each database (51). After that they will be tested for their sensitivity to locate the key papers that the researcher is aware of, along with relevant articles which are consistent with the inclusion criteria just before applying the search in all the selected search engines. An extended list for the search terms will be provided in supported document (appendix) and they will be adapted as required for each databases. The search will be conducted in three separate stages in order to fulfil each objective of the study by recovering the relevant articles for per objective.

2.3 STUDY SELECTION PROCESS:

A random testing will be conducted to check the eligibility criteria before running the search for standardization purpose (52). This process will be applied on the first 100 identified articles and the eligibility criteria will be revised as necessary. A two stages approach technique will be applied which involves the analysis of the title, abstract in the first stage then full text (51). Besides, the references of the identified articles will be screened for caching any relevant papers. The selected articles will be uploaded into online data collection form Rayyan QCRI. The selected inclusion criteria will be applied to the eligible articles. Titles and abstract will be reviewed and screened independently by two reviewers. Conflict regarding the results will be resolved by discussion or a third review if the agreement cannot be achieved. For missing data or unclear information, contact with primary investigator will be made as necessary. After duplicates removal, full texts of all the eligible studies will be uploaded into referencing manager software (Mendeley^R) where they will be assessed further using a piloted check list of the eligibility criteria the PICOCS and the PIC/O. Any conflicts regarding the appropriateness of the selected articles will be sorted by team discussion. The same process will be applied for the full-text screening step.

2.4 ASSESSMENT OF METHODOLOGICAL QUALITY:

Articles selected for retrieval will be assessed for quality before final data extraction process and specific-design study tools will be employed for this purpose. Quality of the studies will be appraised using standardized critical appraisal instruments from the Joanna Briggs Institute Assessment and Review Instrument (JBI) (53), while the risk of bias in each study and across studies will be assessed using the Cochrane EPOC tool (54).

2.5 DATA EXTRACTION:

For each study that meet the inclusion criteria, data will be extracted by two authors, who will be working independently. Data will be extracted using standard form that was created based on study aim and objectives. The following data will be extracted

- ❖ **Study characteristics:** authors, date, settings, country of origins and sample size.
- ❖ **Patient characteristics:** demographic data (age, gender, body weight, height, diseases status, drug regiment (mono vs combined drug regiment), type of antipsychotic prescribed, co-comorbidities that could affect the outcome.
- ❖ **Outcomes of interest:**
 - **Quantitative outcomes:**
 - ❖ **Intervention characteristics':** type of intervention, exposure characteristics including the duration, frequency, intensity and health care professionals involved.

1. Outcomes for intervention effectiveness to reduce cardiovascular and metabolic side effects of the targeted drugs. For example, number of patients screened per visit, patients mean changes from baseline measures or during follow-up period and improvement of quality of life.
 2. All causes of mortality and readmissions due to cardiovascular side effects of antipsychotic and antidepressant drugs such as number of deaths or readmissions after applying the interventions.
- ❖ **Prevalence outcomes:**
1. Outcomes for prevalence or incidence of cardiovascular and metabolic related factors such as (n: %) patients affected.
- **Qualitative** research finding represented as themes metaphors or categories that will be extracted.

2.6 SYNTHESIS OF THE RESULTS:

For the mixed method approach, the model will be applied in this review will rely on the “building and testing” concept (55).

2.6.1 Quantitative data:

Prevalence of cardiovascular and metabolic related complications in patients using antipsychotics and antidepressants and Interventions to reduce cardiovascular and metabolic complications of antipsychotics. We will enter relevant data information into table of the included studies. Meta-analysis will be conducted when suitable, however, it is anticipated to result in methodological heterogeneity due to the wide variety of included studies in this case, narrative synthesis will be adopted.

2.6.2 Qualitative data: Practitioners and patients perspective

Thematic synthesis will be used to synthesis qualitative data into systematic categories [36]. The results of the qualitative synthesis will be utilized to generate recommendations and to provide any explanations for the results obtained from the quantitative data.

3 REFERENCES

1. WHO | Mental health action plan 2013 - 2020. WHO [Internet]. 2015 [cited 2018 Jun 10]; Available from: http://www.who.int/mental_health/publications/action_plan/en/
2. Mental Health Taskforce I. the Five Year Forward View for Mental Health. 2016 [cited 2018 Apr 29]; Available from: <https://www.england.nhs.uk/wp-content/uploads/2016/02/Mental-Health-Taskforce-FYFV-final.pdf>
3. Holck S, Murray C, Murthy RS, Prentice T, Saraceno B, Yach D, et al. WHO Library Cataloguing in Publication Data. 2001 [cited 2018 Apr 8]; Available from: http://www.who.int/whr/2001/en/whr01_en.pdf?ua=1
4. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. *Acta Psychiatr Scand* [Internet]. 2007 Nov [cited 2018 Jul 11];116(5):317–33. Available from: <http://doi.wiley.com/10.1111/j.1600-0447.2007.01095.x>
5. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller H-J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC. 2009 [cited 2018 May 31]; Available from: [https://www.europsy-journal.com/article/S0924-9338\(09\)00017-0/pdf](https://www.europsy-journal.com/article/S0924-9338(09)00017-0/pdf)
6. Wu C-S, Tsai Y-T, Tsai H-J. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. *J Am Heart Assoc* [Internet]. 2015 Feb 23 [cited 2018 Jul 11];4(2):e001568. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25713294>
7. Gruyter D, Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of psychotropic medications. *Horm Mol Biol Clin Investig* [Internet]. 2018 [cited 2018 Apr 14]; Available from: <https://www.degruyter.com/downloadpdf/j/hmbci.ahead-of-print/hmbci-2017-0065/hmbci-2017-0065.pdf>
8. Scigliano G, Ronchetti G. Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis. 2013 [cited 2018 May 18]; Available from: <https://link.springer.com/content/pdf/10.1007%2Fs40263-013-0054-1.pdf>
9. Chang S-C, Lu M-L. Metabolic and Cardiovascular Adverse Effects Associated with Treatment with Antipsychotic Drugs. 2012 [cited 2018 Jul 9]; Available from: https://ac-els-cdn-com.ezproxyd.bham.ac.uk/S1878331712000253/1-s2.0-S1878331712000253-main.pdf?_tid=6a2fe28d-1b29-4b40-96cf-b1f8f0cb6519&acdnat=1531166036_c8b62e6d830d123709f77093bd15ce49
10. Rogério dos Santos Alves; Alex Soares de Souza et all. The Maudsley Prescribing Guidelines in Psychiatry. Igarss 2014. 2014. 1-5 p.
11. Pizzi C, Santarella L, Bugiardini R. Epidemiology and the physiopathological link between depression and cardiovascular disease. *IJC Metab Endocr* [Internet]. 2014 Nov 1 [cited 2018 Jul 6];5:52–5. Available from: <https://www.sciencedirect.com/science/article/pii/S2214762414000462>
12. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. Samet J, editor. *PLoS Med* [Internet]. 2006 Nov 28 [cited 2018 Jul 12];3(11):e442. Available from: <http://dx.plos.org/10.1371/journal.pmed.0030442>
13. Giuseppe M, Gianandrea T, Enrico R, Valeria C, Marzia L, Antonio A, et al. Cardiologic side

- effects of psychotropic drugs. *J Geriatr Cardiol* [Internet]. 2012 Jan 13 [cited 2018 May 12];8(4):243–53. Available from: <http://pub.chinasciencejournal.com/article/getArticleRedirect.action?doiCode=10.3724/SP.J.1263.2011.00243>
14. Wei Xin Chong J, Hsien-Jie Tan E, Eng Chong C. Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects. [cited 2018 Jul 13]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007719/pdf/i2168-9709-6-4-178.pdf>
 15. Glassman AH, Thomas Bigger J. Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death. [cited 2018 Jul 12]; Available from: <https://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.158.11.1774>
 16. Leung JYT, Barr AM, Procyshyn RM, Honer WG, Pang CCY. Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system [Internet]. Vol. 135, *Pharmacology and Therapeutics*. Pergamon; 2012 [cited 2018 Jul 12]. p. 113–22. Available from: <https://www.sciencedirect.com/science/article/pii/S0163725812000800>
 17. Correll CU, Detraux J, Lepeleire J De, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. *World Psychiatry* [Internet]. 2015 [cited 2018 Apr 14];14:119–36. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471960/pdf/wps0014-0119.pdf>
 18. Martínez-Ortega JM, Funes-Godoy S, Díaz-Atienza F, Gutiérrez-Rojas L, Pérez-Costillas L, Gurpegui M. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. *Eur Child Adolesc Psychiatry* [Internet]. 2013 Aug 17 [cited 2018 Jul 14];22(8):457–79. Available from: <http://link.springer.com/10.1007/s00787-013-0399-5>
 19. Nasrallah HA, Meyer JM, Goff DC, Mcevoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. *Schizophr Res* [Internet]. 2006 Sep 1 [cited 2018 May 17];86(1–3):15–22. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16884895>
 20. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. *Am Heart J* [Internet]. 2005 Jan 1 [cited 2018 May 4];149(1):33–45. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15660032>
 21. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophr Res* [Internet]. 2005 Dec 1 [cited 2018 May 4];80(1):19–32. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=16137860>
 22. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. *Am J Med* [Internet]. 2000 Jan 1 [cited 2018 Jul 9];108(1):2–8. Available from: <https://www.sciencedirect.com/science/article/pii/S0002934399003010#BIB13>
 23. Raj SR, Stein CM, Saavedra PJ, Roden DM. Cardiovascular Effects of Noncardiovascular Drugs. *Circulation* [Internet]. 2009 Sep 22;120(12):1123 LP-1132. Available from: <http://circ.ahajournals.org/content/120/12/1123.abstract>

24. Ray W, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. *Clin Pharmacol Ther* [Internet]. 2004 Mar [cited 2018 Jul 8];75(3):234–41. Available from: <http://doi.wiley.com/10.1016/j.clpt.2003.09.019>
25. Thase ME. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients. *J Clin Psychiatry*. 1998;
26. et al Rogério dos Santos Alves; Alex Soares de Souza. *The Maudsley Prescribing Guidelines in Psychiatry*. 2014.
27. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. *J Clin Psychiatry* [Internet]. 2010 Oct [cited 2018 Jul 27];71(10):1259–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21062615>
28. Uguz F, Gungor B, Aksoy F, Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. 2015 [cited 2018 Jul 16]; Available from: <http://dx.doi.org/10.1016/j.genhosppsych.2014.10.011>
29. Hasnain M, Vieweg WVR, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. *Postgrad Med* [Internet]. 2012;124(4):154–67. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=22913904>
30. Van Reedt Dortland AKB, Giltay EJ, Van Veen T, Zitman FG, Penninx BWJH. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. *Acta Psychiatr Scand* [Internet]. 2009 Oct 13 [cited 2018 Jul 16];122(1):30–9. Available from: <http://doi.wiley.com/10.1111/j.1600-0447.2010.01565.x>
31. Depression and Other Common Mental Disorders Global Health Estimates. [cited 2018 Jun 10]; Available from: <http://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf;jsessionid=CDAC71F493E01B234BC5A03A33DF3AF4?sequence=1>
32. Farahani A, Correll CU. Are Antipsychotics or Antidepressants Needed for Psychotic Depression? -A Systematic Review and Meta-Analysis of Trials Comparing Antidepressant or Antipsychotic Monotherapy with Combination Treatment. [cited 2018 Jul 11]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537657/pdf/nihms487578.pdf>
33. et al Rogério dos Santos Alves; Alex Soares de Souza. *The Maudsley Prescribing Guidelines in Psychiatry*. Igarss 2014. 2014. 1-5 p.
34. Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. *BMJ* [Internet]. 2014 Feb 12 [cited 2018 Jul 15];348(feb12 1):g1173–g1173. Available from: <http://www.bmj.com/cgi/doi/10.1136/bmj.g1173>
35. Marano G, Traversi G, Romagnoli E, Catalano V, Lotrionte M, Abbate A, et al. Cardiologic side effects of psychotropic drugs. *J Geriatr Cardiol* 243–253 *J Geriatr CardiolSPJ* [Internet]. 2011 [cited 2018 May 12];83724(10). Available from: www.jgc301.com
36. Pizzi C, Rutjes AWS, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-Analysis of Selective Serotonin Reuptake Inhibitors in Patients With Depression and Coronary Heart Disease. *Am J Cardiol* [Internet]. 2011 Apr 1 [cited 2018 Jul 7];107(7):972–9. Available from: <https://www.sciencedirect.com/science/article/pii/S0002914910025415>
37. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and

- diabetes. *Diabetes Care* [Internet]. 2009;32(6):1037–42. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=19244091>
38. De Hert M, Detraux J, Van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *Nat Rev Endocrinol* [Internet]. 2011 [cited 2018 May 4];8(10). Available from: www.nature.com/nrendo
 39. Bushe C, Haddad Bolton P, Peveler R, Bolton JP. The role of lifestyle interventions and weight management in schizophrenia. [cited 2018 May 31]; Available from: <http://journals.sagepub.com/doi/pdf/10.1177/0269881105058682>
 40. Faulkner G, Cohn TA. Pharmacologic and Nonpharmacologic Strategies for Weight Gain and Metabolic Disturbance in Patients Treated With Antipsychotic Medications Pharmacologic Strategies. *Can J Psychiatry* [Internet]. 2006 [cited 2018 May 15];51(8). Available from: <http://journals.sagepub.com/doi/pdf/10.1177/070674370605100805>
 41. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. *Schizophr Res* [Internet]. 2005 Dec 1 [cited 2018 May 17];80(1):9–18. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=16125372>
 42. Hinds A, Coulter L, Hudson J, Seaton V. Screening for diabetes in patients receiving second-generation atypical antipsychotics. *Am J Health Syst Pharm* [Internet]. 2015;72(17 Suppl 2):S70-3. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=26272895>
 43. Legrix D. [Monitoring of patients using atypical psychotics and screening for metabolic syndrome]. *Suivi des patients sous Trait antipsychotique atypique Depist du Syndr Metab* [Internet]. 2010;(266):25–9. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=20162964>
 44. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. *Cochrane Database Syst Rev* [Internet]. 2010 Dec 8 [cited 2018 Jul 15]; Available from: <http://doi.wiley.com/10.1002/14651858.CD006629.pub2>
 45. Bulletin S, Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. [cited 2018 Jul 4]; Available from: https://watermark.silverchair.com/sby058.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAfQwggHwBgkqhkiG9w0BBwagggHhMIIB3QIBADCCAdYGCSqGSIb3DQEHATAeBgIghkgBZQMEAS4wEQQMEIX8hixXYD4n9JfAgEQgIIBp7USyI3H3LBn CZ0LJfZsZ3XkDKA zYvzjiSgXzLqzB-9pX9KTO2dAquswP657U1TzF5G-cznbfIVZXZsMMZk6k3jUGOWomkhkVLR5FVlqOfCda7vm7Eka6yuihEybrAP7vU6y9kPETK7i77011ctRObLcS49ICGAU-1gMtA1DRcRA7gO61wql3LAYj7n09iM-dFCPPjtho8tD1_zjdyHWNDPSMiWJqNt8eXNt0r_tXIMfphsLzkyeAfn4rFXAYAFE6X0KID8eR_ ocp7bTkVqxV9uri2Sbp1bC_t6tDhWeTkIjVaoIAjIKMZ4MamgyzcKFF03SnDKacfnkiZONCK4aMHrI2KAZ6Va75Fg07a-2tU4AliQSGneUDI4MgjIYPBjBpZOMCtH_fZScTSbOFXn47oaWXrDelzzKao35JJ-5XoTNXCcY_lxsVNA5n0z0LgngHVB0NqeKogd4y89-82HU5n3HAu2_uc2kU0CgtVKW8mwle8GxdXYcfq-

- k_5t4L4rmhzeTxzyQcSlqqJwMDUcwbEczCJ_AuT4M4geaBJvJA3JahOS5pQDATEQ
46. Lvarez-Jimé Nez M, Hetrick SE, Sar Gonzá Lez-Blanch C, Gleeson JF, Mcgorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. *Br J Psychiatry J Clin Psychiatry Am J Psychiatry Schizophr Bull Schizophr Res J Clin Psychopharmacol* [Internet]. 2000 [cited 2018 Jul 13]; Available from: https://www.cambridge.org/core/services/aop-cambridge-core/content/view/0FEE5660C49ABD0D29EEF2137C15F48C/S0007125000235459a.pdf/nonpharmacological_management_of_antipsychoticinduced_weight_gain_systematic_review_and_metaanalysis_of_randomised_controlled_trials.pdf
 47. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;
 48. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: updated March 2011. 2011.
 49. Tacconelli E. Systematic reviews: CRD's guidance for undertaking reviews in health care. *Lancet Infect Dis*. 2010;
 50. Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, et al. Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs. *Arch Gen Psychiatry* [Internet]. 2010 Jan 1 [cited 2018 May 8];67(1):17. Available from: <http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archgenpsychiatry.2009.179>
 51. Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. *J Clin Epidemiol* [Internet]. 2009 Sep 1 [cited 2018 Jul 11];62(9):944–52. Available from: <https://www.sciencedirect.com/science/article/pii/S089543560800320X>
 52. Tricco AC, Soobiah C, Hui W, Antony J, Struchkov V, Hutton B, et al. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT₃) receptor antagonists: a systematic review. *BMC Pharmacol Toxicol* [Internet]. 2015 Dec 26 [cited 2018 May 1];16(1):1. Available from: <http://bmcpharmacoltoxcol.biomedcentral.com/articles/10.1186/2050-6511-16-1>
 53. Porritt K, Gomersall J, Lockwood C. JBI's Systematic Reviews. *AJN, Am J Nurs* [Internet]. 2014 Jun [cited 2018 Jul 11];114(6):47–52. Available from: <http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00000446-201406000-00025>
 54. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* [Internet]. 2011 Oct 18 [cited 2018 Jul 11];343:d5928. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22008217>
 55. Whittemore R, Knafl K. The integrative review: updated methodology. *J Adv Nurs* [Internet]. 2005 Dec [cited 2018 Jul 17];52(5):546–53. Available from: <http://doi.wiley.com/10.1111/j.1365-2648.2005.03621.x>

CONTACT DETAILS FOR FURTHER INFORMATION

Miss Ruba Azfr Ali

Academic Member of Clinical Pharmacy Department

Umm Al-Qura University, Abdia Campus

Makkah, Kingdom of Saudi Arabia.

Rsazfrali@uqu.edu.sa

ORGANISATIONAL AFFILIATION OF THE REVIEW – University of Birmingham.

REVIEW TEAM

Miss Ruba Azfr Ali, Umm Al-Qura University.

Dr Vibhu Paudyal, University of Birmingham

Dr Zahraa Jalal, University of Birmingham.

OTHER INFORMATION

Details of any existing review of the same topic by the same authors - None

Anticipated or actual start date - May 2018

Anticipated completion date - September 2018

Funding sources/sponsors – Saudi Arabian Cultural Bureau in the United Kingdom.

Conflicts of interest - None

Other registration details - None

Language - English

Country - United Kingdom

Key words – antipsychotics; antidepressants; mixed method review; interventions; prevalence; factors; side effect (drug).